Publication:
Methodology of a new inflammatory arthritis registry: TReasure

Simple item page
dc.contributor.authorAKSOY, AYSUN
dc.contributor.authorsKalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali Ihsan; Dalkilic, Huseyin Ediz; Bes, Cemal; Kucuksahin, Orhan; Kasifoglu, Timucin; Alpay Kanitez, Nilufer; Emmungil, Hakan; Kimyon, Gezmis; Yasar Bilge, Nazife Sule; Akar, Servet; Atagunduz, Mehmet Pamir; Koca, Suleyman Serdar; Ates, Askin; Yazisiz, Veli; Terzioglu, Ender; Ersozlu, Emine Duygu; Tufan, Muge Aydin; Cinar, Muhammet; Mercan, Ridvan; Sahin, Ali; Erten, SUkran; Pehlivan, Yavuz; Yilmaz, Sedat; Kelesoglu Dincer, Ayse Bahar; Gercik, Onay; Coskun, Belkis Nihan; Yagiz, Burcu; Kaymaz Tahra, Sema; Aksoy, Aysun; Karadag, Omer; Kilic, Levent; Kiraz, Sedat
dc.date.accessioned2022-04-25T00:11:24Z
dc.date.available2022-04-25T00:11:24Z
dc.date.issued2018
dc.description.abstractBackground/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
dc.identifier.doi10.3906/sag-1807-200
dc.identifier.eissn1303-6165
dc.identifier.issn1300-0144
dc.identifier.pubmed30119164
dc.identifier.urihttps://hdl.handle.net/11424/263897
dc.identifier.wosWOS:000441766000023
dc.languageeng
dc.publisherTUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
dc.relation.ispartofTURKISH JOURNAL OF MEDICAL SCIENCES
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatoid arthritis
dc.subjectspondyloarthritis
dc.subjectdisease-modifying antirheumatic drugs
dc.subjectregistry
dc.subjectTReasure
dc.subjectSOCIETY CLASSIFICATION CRITERIA
dc.subjectNECROSIS FACTOR THERAPY
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectANKYLOSING-SPONDYLITIS
dc.subjectDISEASE-ACTIVITY
dc.subjectPSORIATIC-ARTHRITIS
dc.subjectDIAGNOSTIC-CRITERIA
dc.subjectBIOLOGICS REGISTER
dc.subjectCLINICAL HISTORY
dc.subjectBACK-PAIN
dc.titleMethodology of a new inflammatory arthritis registry: TReasure
dc.typearticle
dspace.entity.typePublication
local.avesis.idfb295ef0-7a60-4395-a760-6550a765fdb3
local.import.packageSS39
local.indexed.atWOS
local.journal.numberofpages6
local.journal.quartileQ4
oaire.citation.endPage861
oaire.citation.issue4
oaire.citation.startPage856
oaire.citation.titleTURKISH JOURNAL OF MEDICAL SCIENCES
oaire.citation.volume48
relation.isAuthorOfPublication8c3b9d86-3f58-4d22-a92a-a6bc58ce5e72
relation.isAuthorOfPublication.latestForDiscovery8c3b9d86-3f58-4d22-a92a-a6bc58ce5e72

Files

Collections

Research Outputs